FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and concerns monoclonal anti-factor XII/XIIa antibody or antigen-binding fragment thereof, affinity of binding to factor XIIa-beta of a human being is 2 times greater than the affinity of binding to human factor XII and which is able to completely inhibit the amidolytic activity of human factor XIIa. Group of inventions also concerns monoclonal anti-factor XII/XIIa antibody or an antigen-binding fragment thereof that inhibits the amidolytic activity of factor XIIa-alpha by 50% more when used in a molar ratio of FXIIa-alpha to antibody 1:0.2. Group of inventions also concerns pharmaceutical composition for the prevention or treatment of an ailment associated with FXII/FXIIa containing said antibody.
EFFECT: group of inventions provides inhibition of the activated FXIIa, but not a decrease in the level of FXII in the blood.
25 cl, 16 dwg, 14 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL HUMANISED ANTIBODIES TO FACTOR XI WITH ANTITHROMBOTIC AND ANTI-INFLAMMATORY ACTION AND USE THEREOF | 2020 |
|
RU2817219C2 |
| ANTIBODIES AGAINST XI CLOTTING FACTOR | 2017 |
|
RU2757314C2 |
| ANTIBODIES TO CD70 | 2012 |
|
RU2604196C2 |
| ANTI c-Met RECEPTOR PROTEIN ANTIBODIES | 2011 |
|
RU2608644C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| MONOCLONAL ANTIBODIES BINDING WITH hGM-CSF AND COMPOSITIONS FOR MEDICINAL PURPOSES, CONTAINING THEREOF | 2008 |
|
RU2517596C2 |
| ANTIBODIES AGAINST FACTOR D AND THEIR USE | 2018 |
|
RU2799044C2 |
| ANTI-VEGF-ANTIBODY AND ITS PHARMACEUTICAL COMPOSITION FOR PREVENTION, DIAGNOSTICS OR TREATMENT OF CANCER OR ANGIOGENESIS-RELATED DISEASE | 2014 |
|
RU2644245C2 |
| ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2739946C2 |
| ANTIBODIES PRIMARILY BINDING TO EXTRACELLULAR DOMAIN 4 OF HUMAN CSF-1R, AND USING THEM | 2010 |
|
RU2565541C2 |
